MIMOS, a Malaysian national applied research and development agency, has unveiled a new GlucoSenz device for blood glucose screening.
GlucoSenz, which is a non-invasive, non-intrusive and non-destructive device, is claimed to be world’s first clinically-tested non-invasive blood screening prototype.
GlucoSenz device uses chemometrics methods to study the near-infrared (NIRS) obtained in absorbance mode via the user’s thumb spectra.
Through using photonics, electronics and software technologies, the device will detect, analyse and predict blood glucose level from the blood capillaries of the human thumb without piercing the skin.
MIMOS noted that the new device has been developed at its photonics technology laboratory through seven-year research and development.
The thumb will be placed on the thumb module for projecting light. Later, the reflected light is collected by a fibre-optic probe that guides the light to a detector.
The light spectrum is then analysed by a built-in software module, and the blood glucose level result in mmol/l can be seen on the LCD display.
MIMOS secured ethical approval for the device from the Malaysia Medical Device Association Universiti Putra Malaysia (UPM)’s Faculty of Veterinary Medicine, Cyberjaya University College of Medical Science (CUCMS) and the UKM Medical Centre (HUKM).
MIMOS R&D senior director Mohd Shahiman Sulaiman said: “The launch of GlucoSenz marks a huge step forward for MIMOS’ Advanced Electrical and Electronics division, particularly the photonics R&D team.
“At this stage, the solution can bring a significant impact to healthcare providers, where safety and economics are of paramount importance.
Shahiman has also said that the works are undergoing to miniaturize the device and intends to produce the first mini prototype for trial by mid-2019.
GlucoSenz is expected to be launched into the market by the end of 2019.
Shahiman further added: “GlucoSenz would potentially replace conventional glucometers due to its ease of use and high accuracy. Countries with high rates of diabetes and obesity should keep a watch on this product as it has a huge market potential.”
MIMOS is a strategic agency under the Ministry of International Trade and Industry (MITI), ands has filed over 2,000 intellectual properties in various technology domains and across key socio-economic areas.